GenXys is a private health tech company that provides AI-driven precision prescribing software and pharmacogenomic solutions. Its tools help healthcare organizations improve medication selection, safety review, and authorization workflows.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Latest Price
$21B
Private Equity, Dec 6, 2021, Perplexity
UpMarket Estimate
$22B
Based on UpMarket valuation model
Previous Price
Series C 2021
How to Invest in GenXys Through UpMarket
GenXys shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Step 01
Verify accredited investor status
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Step 02
Create an UpMarket account
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Step 03
Review available GenXys offerings
Full offering memoranda and risk disclosures provided before any commitment is required.
Step 04
Complete subscription documents
Review and sign subscription agreement. All documents handled digitally through the platform.
Step 05
Fund your investment
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
$1.3B+
UpMarket has brokered over $1.3 billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through March 31, 2026. Of the total, approximately $301 million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Dec 6, 2021
Private Equity
$21B
2021
Series C
2020
Series B
2019
Series A
Why Investors Are Watching GenXys
Growth Signal
GenXys revenue rose to $2.5M ARR in 2024
GenXys Health Care Systems reported 2024 revenue of $2.5M ARR, up from $1.5M in 2023. The company also disclosed total funding of $3.6M across 2 rounds, showing early commercial traction with limited capital.
GenXys said it closed an oversubscribed seed round at $3 million to support continued market penetration. The company described its product as pharmacogenetic enhanced prescribing automation software.
Team & Talent
CEO Martin Dawes leads a 18-person GenXys team
A company interview said GenXys had a team of 18 professionals, with many based in the company’s core operating group. Preqin also lists CEO Martin Dawes as the leader of the business, indicating a small executive-led organization.
Interested in GenXys stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, GenXys is a private company and does not trade on any public stock exchange. Accredited investors can access GenXys shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
GenXys does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in GenXys shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered more than $500M in alternative investments since 2019.
Pre-IPO investments carry significant risks. GenXys shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
GenXys provides AI-driven precision prescribing software and pharmacogenomic solutions, with revenue rising to $2.5M ARR in 2024 and a $22B valuation underscoring its position in personalized medicine — accredited investors can access GenXys stock through UpMarket.